Advertisement

International Orthopaedics

, Volume 42, Issue 7, pp 1575–1583 | Cite as

Investigating clinical failure of core decompression with autologous bone marrow mononuclear cells grafting for the treatment of non-traumatic osteonecrosis of the femoral head

  • Lihua Liu
  • Fuqiang Gao
  • Wei Sun
  • Yunting Wang
  • Qingyu Zhang
  • Bailiang Wang
  • Liming Cheng
  • Zi-rong Li
Original Paper

Abstract

Objective

This study aimed to analyze the clinical factors related to the failure of autologous bone marrow mononuclear cells grafting (BMMCG) following core decompression (CD) in early stage osteonecrosis of the femoral head (ONFH).

Methods

In total, 148 patients (192 hips) underwent CD with autologous BMMCG for treatment of non-traumatic ONFH. The patients were classified by their ARCO staging and China-Japan Friendship Hospital (CJFH) typing system. All patients were clinically and radiographically followed up every three months during the first year and every six months in the following years. The clinical evaluation was conducted by pre- and post-operative Harris hip scores (HHS), while serial anteroposterior (AP) and frog lateral radiographs were used for post-operative radiographic evaluation.

Results

There were 56 hips as clinical failure cases, and 50 hips (89.29%) of failure cases developed between three and ten months after operation. Based on CJFH classification system, type L2 showed more failure rate with 60.0% (9 of15). The Cox risk model showed that disease type was an independent risk factor for post-operative clinical failure (P = 0.042). Multivariate analysis of the Cox proportional-hazards model showed that type L1 had a hazard ratio (HR) of 0.286 (95% CI 0.100–0.816), type L3 with HR of 0.245 (95% CI 0.079–0.759), respectively.

Conclusion

Disease type is an important risk factor for autologous BMMCG combined with CD, and the degree of lateral pillar necrosis is a significant reference index for prognosis evaluation in early stage of ONFH.

Keywords

Osteonecrosis of the femoral head Bone marrow Prognosis Treatment Risk factor 

Notes

Funding information

This study was supported by the National Natural Science Foundation of China (81672236, 81372013), and Beijing Natural Science Foundation (7182146).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The procedures performed in this study involving human participants were approved by the ethics committee of China-Japan Friendship Hospital. (File 1)

Informed consent

Informed consent was obtained from all individual participants included in the study. (File 2)

References

  1. 1.
    Mont MA, Zywiel MG, Marker DR, McGrath MS, Delanois RE (2010) The natural history of untreated asymptomatic osteonecrosis of the femoral head: a systematic literature review. J Bone Joint Surg Am 92(12):2165–2170.  https://doi.org/10.2106/JBJS.I.00575 CrossRefPubMedGoogle Scholar
  2. 2.
    Lieberman JR, Engstrom SM, Meneghini RM, SooHoo NF (2012) Which factors influence preservation of the osteonecrotic femoral head? Clin Orthop Relat Res 470(2):525–534.  https://doi.org/10.1007/s11999-011-2050-4 CrossRefPubMedGoogle Scholar
  3. 3.
    Tomaru Y, Yoshioka T, Sugaya H, Aoto K, Wada H, Akaogi H et al (2017) Hip preserving surgery with concentrated autologous bone marrow aspirate transplantation for the treatment of asymptomatic osteonecrosis of the femoral head: retrospective review of clinical and radiological outcomes at 6 years postoperatively. BMC Musculoskelet Disord 18(1):292.  https://doi.org/10.1186/s12891-017-1652-8 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ficat P, Arlet J, Vidal R, Ricci A, Fournial JC (1971) Therapeutic results of drill biopsy in primary osteonecrosis of the femoral head (100 cases). Rev Rhum Mal Osteoartic 38(4):269–276PubMedGoogle Scholar
  5. 5.
    Al OA (2013) Multiple drilling compared with standard core decompression for avascular necrosis of the femoral head in sickle cell disease patients. Arch Orthop Trauma Surg 133(5):609–613.  https://doi.org/10.1007/s00402-013-1714-9 CrossRefGoogle Scholar
  6. 6.
    Hernigou P, Beaujean F (2002) Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res 405:14–23CrossRefGoogle Scholar
  7. 7.
    Hernigou P, Poignard A, Zilber S, Rouard H (2009) Cell therapy of hip osteonecrosis with autologous bone marrow grafting. Indian J Orthop 43(1):40–45.  https://doi.org/10.4103/0019-5413.45322 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Wang BL, Sun W, Shi ZC, Zhang NF, Yue DB, Guo WS et al (2010) Treatment of nontraumatic osteonecrosis of the femoral head with the implantation of core decompression and concentrated autologous bone marrow containing mononuclear cells. Arch Orthop Trauma Surg 130(7):859–865.  https://doi.org/10.1007/s00402-009-0939-0 CrossRefPubMedGoogle Scholar
  9. 9.
    Sen RK, Tripathy SK, Aggarwal S, Marwaha N, Sharma RR, Khandelwal N (2012) Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomized control study. J Arthroplasty 27(5):679–686.  https://doi.org/10.1016/j.arth.2011.08.008 CrossRefPubMedGoogle Scholar
  10. 10.
    Beckmann J, Schmidt T, Schaumburger J, Rath B, Luring C, Tingart M et al (2013) Infusion, core decompression, or infusion following core decompression in the treatment of bone edema syndrome and early avascular osteonecrosis of the femoral head. Rheumatol Int 33(6):1561–1565.  https://doi.org/10.1007/s00296-012-2597-8 CrossRefPubMedGoogle Scholar
  11. 11.
    Hernigou P, Trousselier M, Roubineau F, Bouthors C, Chevallier N, Rouard H et al (2016) Stem cell therapy for the treatment of hip osteonecrosis: a 30-year review of progress. Clin Orthop Surg 8(1):1–8.  https://doi.org/10.4055/cios.2016.8.1.1 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Houdek MT, Wyles CC, Packard BD, Terzic A, Behfar A, Sierra RJ (2016) Decreased osteogenic activity of mesenchymal stem cells in patients with corticosteroid-induced osteonecrosis of the femoral head. J Arthroplast 31(4):893–898.  https://doi.org/10.1016/j.arth.2015.08.017 CrossRefGoogle Scholar
  13. 13.
    Piuzzi NS, Chahla J, Schrock JB, LaPrade RF, Pascual-Garrido C, Mont MA et al (2017) Evidence for the use of cell-based therapy for the treatment of osteonecrosis of the femoral head: a systematic review of the literature. J Arthroplast 32(5):1698–1708.  https://doi.org/10.1016/j.arth.2016.12.049 CrossRefGoogle Scholar
  14. 14.
    Sun W, Li ZR, Gao FQ, Shi ZC, Wang BL, Guo WS (2014) Porous bioceramic beta-tricalcium phosphate for treatment of osteonecrosis of the femoral head. Zhongguo Zuzhi Gongcheng Yanjiu 16:2474–2479.  https://doi.org/10.3969/j.issn.2095-4344.2014.16.003 CrossRefGoogle Scholar
  15. 15.
    Hernigou P, Flouzat-Lachaniette CH, Delambre J, Poignard A, Allain J, Chevallier N et al (2015) Osteonecrosis repair with bone marrow cell therapies: state of the clinical art. Bone 70:102–109.  https://doi.org/10.1016/j.bone.2014.04.034 CrossRefPubMedGoogle Scholar
  16. 16.
    Piuzzi NS, Chahla J, Jiandong H, Chughtai M, LaPrade RF, Mont MA et al (2017) Analysis of cell therapies used in clinical trials for the treatment of osteonecrosis of the femoral head: a systematic review of the literature. J Arthroplast.  https://doi.org/10.1016/j.arth.2017.02.075
  17. 17.
    Hernigou P, Beaujean F, Lambotte JC (1999) Decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. J Bone Joint Surg Br 81(2):349–355CrossRefPubMedGoogle Scholar
  18. 18.
    Wang BL, Li TJ, Yue DB, Sun W (2014) Proliferation ability of bone marrow mesenchymal stem cells in corticosteroid-induced osteonecrosis of femoral head. Zhongguo Zuzhi Gongcheng Yanjiu 1:7–13.  https://doi.org/10.3969/j.issn.2095-4344.2014.01.002 CrossRefGoogle Scholar
  19. 19.
    Gangji V, De Maertelaer V, Hauzeur JP (2011) Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: five year follow-up of a prospective controlled study. Bone 49(5):1005–1009.  https://doi.org/10.1016/j.bone.2011.07.032 CrossRefPubMedGoogle Scholar
  20. 20.
    Maus U, Roth A, Tingart M, Rader C, Jager M, Noth U et al (2015) S3 guideline. Part 3: non-traumatic avascular necrosis in adults—surgical treatment of atraumatic avascular femoral head necrosis in adults. Z Orthop Unfall 153(5):498–507.  https://doi.org/10.1055/s-0035-1545902 CrossRefPubMedGoogle Scholar
  21. 21.
    Sun W, Li ZR, Wang BL, Liu BL, Zhang QD, Guo WS (2014) Relationship between preservation of the lateral pillar and collapse of the femoral head in patients with osteonecrosis. Orthopedics 37(1):e24–e28CrossRefPubMedGoogle Scholar
  22. 22.
    Bozic KJ, Zurakowski D, Thornhill TS (1999) Survivorship analysis of hips treated with core decompression for nontraumatic osteonecrosis of the femoral head. J Bone Joint Surg Am 81(2):200–209CrossRefPubMedGoogle Scholar

Copyright information

© SICOT aisbl 2018

Authors and Affiliations

  • Lihua Liu
    • 1
  • Fuqiang Gao
    • 2
  • Wei Sun
    • 3
  • Yunting Wang
    • 3
  • Qingyu Zhang
    • 1
  • Bailiang Wang
    • 2
  • Liming Cheng
    • 2
  • Zi-rong Li
    • 2
  1. 1.Graduate School of Peking Union Medical CollegeChina-Japan Friendship institute of Clinical MedicineBeijingChina
  2. 2.Centre for Osteonecrosis and Joint-preserving & Reconstruction, Orthopaedic DepartmentChina-Japan Friendship HospitalBeijingChina
  3. 3.Centre for Osteonecrosis and Joint-preserving & Reconstruction, Orthopaedic Department, China-Japan Friendship HospitalGraduate School of Peking Union Medical CollegeBeijingChina

Personalised recommendations